A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
The Latest on: Vaccine development
Kenya Doesn't Have a Flu Vaccine Policy. Why It Needs One for Babies
on April 19, 2018 at 4:14 am
To address these fluctuations, the vaccine development world is looking into the viability of a universal flu vaccine. This would be effective against all circulating flu strains. The universal vaccine would require vaccination either once in a lifetime or ... […]
Detailed examination of the chick embryo cell rabies vaccine market size,status , trends and forecast to 2025
on April 18, 2018 at 10:35 pm
It includes marketing channel (direct marketing, indirect marketing, and marketing channel development trend) and market positioning (pricing strategy, brand strategy, and target client). The Chick Embryo Cell Rabies Vaccine Market report also covers an ... […]
Anti-vaccine misinformation denies children’s rights
on April 18, 2018 at 1:41 pm
Peter J. Hotez, M.D., Ph.D., is professor and dean of the National School of Tropical Medicine at Baylor College of Medicine, and director of the Texas Children’s Hospital Center for Vaccine Development. In an age of air travel, this puts every ... […]
Gates Sees Vaccine Technology Promise as Drug Resistance Rises
on April 18, 2018 at 10:06 am
Vaccines that use a mirror image of DNA to halt the growth of bacteria and viruses appear capable of speeding development of the prevention tools dramatically, Gates said in an interview. Moderna Therapeutics Inc. and CureVac GmbH are two companies ... […]
Africa: Why Manufacturing a Key Vaccine in South Africa Is So Important
on April 18, 2018 at 12:51 am
It will manage vaccine research and development, manufacturing and supply. Local vaccine manufacture has several foreseeable benefits. These include decreased cost and increased availability and the capability to provide vaccines to the region. The local ... […]
via Google News and Bing News